Aug 27 2026
Healthcare
Recent Research
Malin Corporation, H1 2026 results
Aug 26 2026
Uniphar, Interim trading statement
Jul 28 2026
hVIVO, H1 2026 trading update
Jul 23 2026
CVS Group, FY2026 trading statement
Jul 23 2026
CVS Group, Announcement of share buyback
May 26 2026
Meet your Healthcare Research team
hVIVO
Acquisition of CRS Berlin
hVIVO has announced the acquisition of CRS (Clinical Research Services) Berlin for a nominal upfront consideration and potential earn-out. It is a strategic bolt-on acquisition that has...
Malin Corporation
H1 2026 results
Malin has reported its H1 2026 results reflecting a NAV/share of €9.36, which is 2% growth during the period. However, the company previously reported on July 27th that it was writing...
Uniphar
Interim trading statement
Uniphar’s trading statement for H1 2026 reflects strong operating performance. The outlook is positive on all divisions. The timing of going live on Greenogue II has been extended to...
Malin Corporation
Update on contingent consideration receivable regarding Kymab
Malin has provided an update on its contingent consideration receivable regarding its former investee company, Kymab. Following a decision by Kymab’s owner, Sanofi, Malin will reduce the...
hVIVO
H1 2026 trading update
hVIVO has issued a trading update for H1 2026. Earnings are in line with expectations. There has been an increase in commercial momentum with a significant expansion in the orderbook....
CVS Group
FY2026 trading statement
CVS has issued a trading statement for FY2026, reflecting results that are in line with our forecasts. There was positive EPS growth in FY2026 despite weak consumer spending in the...
CVS Group
Announcement of share buyback
CVS has announced that it is commencing a share buyback of up to £50m (6% of its market cap). This is positive. There has been further progress on acquisitions in Australia, and CVS...
Uniphar
AGM statement
Uniphar has published a trading statement ahead of its AGM later today. It notes its strong performance in 2025 and 16% CAGR in EPS since 2019. It also indicates that the first four...
Uniphar
Significant upgrades to forecasts and price target
We upgrade our Uniphar EPS forecasts by 7-8% in 2026 and 2027, driven by strong EBITDA growth and lower-than-expected finance charges. This is our fourth upgrade since the start of...
hVIVO
FY2025 results
hVIVO has reported FY2025 results that are in line with the figures given in its January trading statement as well as our forecasts. Revenues declined due to order cancellations....
